先声药业(02096.HK)滥用原料药销售支配地位 遭国家市监局罚款逾亿元人币
先声药业(02096.HK)公布,今年1月29日,公司收到国家市场监督管理总局出具的《行政处罚决定书》。根据通知,国家市监局认定公司滥用在中国巴曲(酉每)浓缩液原料药销售市场的支配地位,实施了没有正当理由拒绝与相关交易相对人进行交易的行为,违反了反垄断法的相关条文。国家市监局责令公司停止违法行为,并对公司处以相当於公司截至2019年年底止年度收入2%的罚款约1.007亿元人民币。
公司指,已开始与第三方进行巴曲(酉每)浓缩液原料药交易,并将根据通知及时缴纳行政处罚。考虑到行政处罚的金额,公司认为有关事件及行政处罚不会对公司的业务经营及财务状况产生任何重大影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.